Similar Papers

Paper Title
Journal
Date
Author
Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia.
Jung Yong Hong ... Silvia Park
OncoTargets and Therapy | VOL. 7
Jung Yong Hong, et. al.Jung Yong Hong ... Silvia Park
01 Sep 2014
PCN143 - Cost-Effectiveness Analysis of Brentuximab Vedotin in Adults with Relapsed or Refractory Hodgkin’s Lymphoma
Gr Khachatryan ... Vs Dombrovskiy
Value in Health | VOL. 19
Gr Khachatryan, et. al.Gr Khachatryan ... Vs Dombrovskiy
31 Oct 2016
COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
G R Khachatryan ... V S Dombrovskiy
PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology | VOL. 9
G R Khachatryan, et. al.G R Khachatryan ... V S Dombrovskiy
01 Jan 2015
Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study.
Roy Khalife ... Harold Atkins
British journal of haematology | VOL. 191
Roy Khalife, et. al.Roy Khalife ... Harold Atkins
20 Jul 2020
View more papers

More From: Clinical Lymphoma, Myeloma and Leukemia

Paper Title
Journal
Date
Author
SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia
Andrew H Lipsky ... Nicole Lamanna
Clinical Lymphoma, Myeloma and Leukemia | VOL. -
Andrew H Lipsky, et. al.Andrew H Lipsky ... Nicole Lamanna
01 Dec 2024
Table of Contents
-
Clinical Lymphoma, Myeloma and Leukemia | VOL. 24
--
01 Dec 2024
A phase I study of romidepsin in combination with gemcitabine, oxaliplatin, and dexamethasone in patients with relapsed or refractory aggressive lymphomas enriched for T-cell lymphomas.
Nicole Foley ... Neha Mehta-Shah
Clinical Lymphoma, Myeloma and Leukemia | VOL. -
Nicole Foley, et. al.Nicole Foley ... Neha Mehta-Shah
01 Dec 2024
Editorial Board
-
Clinical Lymphoma, Myeloma and Leukemia | VOL. 24
--
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.